Neuland Laboratories Stock Screener | Share Price & Fundamental Analysis
NEULANDLAB
Pharmaceuticals
Screen Neuland Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹15040.00
▼
-236.00 (-1.54%)
Share Price BSE
₹15039.55
▼
-226.05 (-1.48%)
Market Cap
₹19,321.81 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
12.04
EPS (TTM)
₹202.74
Dividend Yield
0.08%
Debt to Equity
0.09
52W High
₹18113.00
52W Low
₹10487.30
Operating Margin
30.00%
Profit Margin
18.80%
Revenue (TTM)
₹516.00
EBITDA
₹157.00
Net Income
₹97.00
Total Assets
₹2,180.00
Total Equity
₹1,525.00
Neuland Laboratories Share Price History - Stock Screener Chart
Screen NEULANDLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Neuland Laboratories Company Profile - Fundamental Screener
Screen Neuland Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NEULANDLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE794A01010
Neuland Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen NEULANDLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,180 | 1,833 | 1,580 | 1,384 | 1,325 | 1,231 | 1,130 | 1,071 | 886 | 524 |
| Current Assets | 1,140 | 921 | 761 | 581 | 550 | 515 | 454 | 447 | 375 | 314 |
| Fixed Assets | 955 | 824 | 758 | 767 | 716 | 653 | 542 | 475 | 466 | 139 |
| Liabilities | ||||||||||
| Total Liabilities | 2,180 | 1,833 | 1,580 | 1,384 | 1,325 | 1,231 | 1,130 | 1,071 | 886 | 524 |
| Current Liabilities | 189 | 122 | 147 | 180 | 170 | 163 | 104 | 146 | 54 | 69 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,525 | 1,283 | 994 | 841 | 787 | 710 | 699 | 558 | 546 | 187 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 9 | 9 | 9 |
| Reserves & Surplus | 1,512 | 1,270 | 981 | 828 | 774 | 697 | 686 | 549 | 537 | 178 |
Screen NEULANDLAB income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516 | 301 | 336 | 458 | 315 | 465 | 390 | 395 | 421 | 365 | 415 | 270 | 294 | 222 | 257 |
| Expenses | 359 | 258 | 277 | 311 | 249 | 316 | 278 | 272 | 280 | 266 | 287 | 215 | 224 | 193 | 217 |
| EBITDA | 157 | 42 | 59 | 146 | 67 | 149 | 112 | 123 | 141 | 99 | 128 | 55 | 70 | 29 | 40 |
| Operating Profit % | 30.00% | 12.00% | 16.00% | 22.00% | 20.00% | 28.00% | 28.00% | 31.00% | 33.00% | 27.00% | 29.00% | 20.00% | 24.00% | 13.00% | 15.00% |
| Depreciation | 23 | 20 | 17 | 16 | 16 | 16 | 17 | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 12 |
| Interest | 5 | 5 | 2 | 2 | 1 | 3 | 4 | 4 | 4 | 2 | 4 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 129 | 18 | 39 | 128 | 49 | 130 | 92 | 105 | 122 | 83 | 110 | 39 | 53 | 14 | 24 |
| Tax | 33 | 4 | 12 | 26 | 17 | 32 | 25 | 23 | 32 | 21 | 26 | 8 | 15 | 4 | 3 |
| Net Profit | 97 | 14 | 28 | 102 | 33 | 98 | 68 | 81 | 89 | 62 | 85 | 31 | 39 | 10 | 22 |
| EPS | 75.49 | 10.83 | 21.67 | 79.18 | 25.60 | 76.28 | 52.66 | 63.44 | 69.56 | 48.23 | 65.90 | 23.81 | 29.97 | 7.77 | 16.97 |
Neuland Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen NEULANDLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 317 | 261 | 237 | 60 | 189 | 57 | 70 | 11 | 39 | 45 |
| Investing Activities | -298 | -150 | -61 | -95 | -85 | -49 | -77 | -116 | -42 | -20 |
| Financing Activities | 25 | -69 | -136 | 38 | -114 | -6 | 12 | 105 | 0 | -24 |
| Net Cash Flow | 44 | 42 | 40 | 3 | -9 | 3 | 5 | 0 | -4 | 1 |
Screen NEULANDLAB shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 32.68% | 32.68% | 32.64% | 32.74% | 32.72% | 32.64% | 32.68% | 36.14% |
| FII Holding | 22.11% | 21.69% | 20.60% | 24.44% | 25.72% | 26.46% | 23.86% | 0.00% |
| DII Holding | 10.97% | 11.57% | 13.54% | 6.54% | 6.39% | 6.38% | 9.08% | 7.10% |
| Govt Holding | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% |
| Public Holding | 25.86% | 25.55% | 24.72% | 27.97% | 27.05% | 26.50% | 26.05% | 29.86% |
| Other Holding | 7.99% | 8.12% | 8.09% | 7.91% | 7.71% | 7.61% | 7.93% | 26.51% |
| Shareholder Count | 39,333 | 42,419 | 44,393 | 28,616 | 29,077 | 34,567 | 39,315 | 26,948 |
Neuland Laboratories Dividend Screener - Share Yield Analysis
Screen NEULANDLAB dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹12.00 | 0.08% |
| 2024-March | ₹14.00 | 0.12% |
| 2023-March | ₹10.00 | 0.16% |
| 2022-March | ₹5.00 | 0.28% |
| 2021-March | ₹5.00 | 0.49% |
| 2020-March | ₹2.00 | 0.10% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Neuland Laboratories Index Membership - Market Screener Classification
Screen NEULANDLAB by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Neuland Laboratories Market Events Screener - Corporate Actions
Screen NEULANDLAB market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 8.38% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | 13.07% |
| 2025-07-30 | 2025-07-30 | Annual General Meeting | NA | 11.04% |
| 2025-07-18 | 2025-07-18 | Dividend | ₹ 12.00 /share | 16.23% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | -2.72% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 2.73% |
| 2024-11-06 | 2024-11-06 | Quarterly Result Announcement | NA | -2.42% |
| 2024-07-31 | 2024-07-31 | Annual General Meeting | NA | 26.65% |
| 2024-07-12 | 2024-07-13 | Dividend | ₹ 14.00 /share | 13.26% |
| 2023-07-11 | 2023-07-12 | Dividend | ₹ 10.00 /share | 41.77% |
| 2022-07-14 | 2022-07-15 | Dividend | ₹ 5.00 /share | -2.72% |
| 2021-06-29 | 2021-07-01 | Dividend | ₹ 3.00 /share | -20.44% |
Neuland Laboratories Competitors Screener - Peer Comparison
Screen NEULANDLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Neuland Laboratories Company Announcements - News Screener
Screen NEULANDLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-01 | Closure of Trading Window | View |
| 2025-12-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-08 | Re-Lodgement Of Transfer Request Of Physical Shares | View |
| 2025-12-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-28 | Disclosure Under Regulation 30 Of SEBI Listing Regulations | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-21 | Re-Lodgement Of Transfer Request Of Physical Shares | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-07 | Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-07 | Board Meeting Outcome for Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-05 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | View |
| 2025-11-05 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | View |